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Abstract 
Background: Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dys-
function and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate 
the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on 
cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitaglip-
tin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the 
PROLOGUE study.
Methods: Patients in the PROLOGUE study were assigned randomly to either add-on sitagliptin treatment or con-
ventional antidiabetic treatment. Of the 463 patients in the overall study, 115 patients (55 in the sitagliptin group and 
60 in the conventional group) who had complete echocardiographic data of the ratio of peak early diastolic trans-
mitral flow velocity (E) to peak early diastolic mitral annular velocity (e′) at baseline and after 12 and 24 months were 
included in this study. The primary endpoint of this post hoc sub-analysis was a comparison of the changes in the 
ratio of E to e′ (E/e′) between the two groups from baseline to 24 months.
Results: The baseline-adjusted change in E/e′ during 24 months was significantly lower in the sitagliptin group than 
in the conventional group (−0.18 ± 0.55 vs. 1.91 ± 0.53, p = 0.008), irrespective of a higher E/e′ value at baseline in 
the sitagliptin group. In analysis of covariance, sitagliptin treatment was significantly associated with change in E/e′ 
over 24 months (β = −9.959, p = 0.001), independent of other clinical variables at baseline such as blood pressure, 
HbA1c, and medications for diabetes. Changes in other clinical variables including blood pressure and glycemic 
parameters, and echocardiographic parameters, such as cardiac structure and systolic function, were comparable 
between the two groups. There was also no significant difference in the serum levels of N-terminal-pro brain natriu-
retic peptide and high-sensitive C-reactive protein between the two groups during the study period.
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Background
Type 2 diabetes mellitus (T2DM) is associated closely 
with an increased risk of cardiovascular (CV) events 
including heart failure [1, 2]. The prevalence of patients 
who develop heart failure is greater in diabetic indi-
viduals than in non-diabetic individuals, and diabetes is 
known to be a strong risk factor for the development of 
heart failure [3]. It has been shown that once individu-
als with T2DM developed heart failure their 5-year sur-
vival rate was 12.5%, a rate considerably lower than in 
individuals without heart failure [3]. Furthermore, diabe-
tes contributes to a worse outcome in patients with left 
ventricular (LV) diastolic dysfunction than those with 
systolic dysfunction [5]. However, intensive glucose-low-
ering therapy with antidiabetic agents does not always 
reduce the risk of heart failure [6], with some agents 
having unfavorable clinical effects on heart failure [7, 8]. 
Therefore, it is important to evaluate the impact of anti-
diabetic agents on cardiac function [9, 10].
To date, three randomized controlled trials that focused 
on major CV outcomes in patients with T2DM treated 
with either dipeptidyl peptidase-4 (DPP-4) inhibitors or 
placebo have been reported. Alogliptin in the EXAMIN 
[11], saxagliptin in the SAVOR-TIMI 53 [12], and sitag-
liptin in the TECOS [13] all showed non-inferior to pla-
cebo to lower the risk of the composite primary endpoint 
of CV death, myocardial infarction or ischemic stroke. 
However, in the SAVOR-TIMI 53 trial a 27% increase in 
the rate of hospital admission for heart failure was found 
in the group with saxagliptin [14]. Results from meta-
analyses of randomized trials also demonstrated that 
DPP-4 inhibitors were associated with an increased risk 
of heart failure [15, 16]. In contrast, there was no sig-
nificant difference in the rate of hospital admissions for 
heart failure between sitagliptin and placebo groups in 
the TECOS trial. Taken together, these results show the 
influence of DPP-4 inhibitors on cardiac function is still a 
major clinical concern.
The PROLOGUE study (University hospital Medical 
Information Network Center: ID 000004490) was a pro-
spective multicenter study conducted in Japan to evalu-
ate the inhibitory effect of sitagliptin on the progression 
of atherosclerosis based on carotid-artery intima-media 
thickness (IMT) assessed by ultrasonography over a 
2-year follow-up period [17, 18]. In this study, echocardi-
ography at baseline and after 12 and 24 months of treat-
ment was an optional examination. In order to elucidate 
the effect of DPP-4 inhibitor on cardiac function we car-
ried out a sub-study of the PROLOGUE study that inves-
tigated the effect of sitagliptin on two-dimensional and 
Doppler echocardiographic parameters, mainly focus-




The details of the PROLOGUE study design have been 
published elsewhere [17]. Briefly, the study was a mul-
ticenter, randomized, prospective, open-label, blinded-
endpoint trial carried out at 48 institutions in Japan. A 
total of 463 patients older than 30 years who had T2DM 
with an HbA1c level of 6.2–9.4% despite conventional 
treatment with diet, exercise, and/or pharmacologic 
therapy with oral antidiabetic agents (except incretin-
related therapy) for more than 3  months were enrolled 
in the study between June 2011 and September 2012. 
Patients with severe heart failure with a New York Heart 
Association (NYHA) functional classification of III and 
IV were excluded. The inclusion and exclusion criteria 
for the study have been published previously [17, 18]. 
The patients were assigned randomly using a 1:1 ratio 
to either add-on sitagliptin treatment (sitagliptin group, 
n  =  232) or conventional glucose-lowering treatment 
(conventional group, n = 231). The primary endpoint of 
the PROLOGUE study was the change in mean common 
carotid IMT 24  months after treatment randomization. 
Echocardiography was performed as an ad hoc exami-
nation at baseline and 12 and 24 months after treatment 
randomization. The ethical committees of each partici-
pating institution approved the study protocol, with writ-
ten informed consent for participation in the study being 
obtained from all the subjects.
Study population
Of the 436 participants in the PROLOGUE study, an 
echocardiographic examination was performed at base-
line in 152 patients in the sitagliptin group and 148 
patients in the conventional group. The present study 
Conclusions: Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenu-
ated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e′) independent of other 
clinical variables such as blood pressure and glycemic control.
Trial registration UMIN000004490 (University Hospital Medical Information Network Clinical Trials). https://upload.umin.
ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356; registered November 1, 2010
Keywords: Sitagliptin, T2DM, Echocardiography, Diastolic function, NT-proBNP
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analyzed the data of 115 patients (55 patients in the sit-
agliptin group and 60 patients in the conventional group) 
who had echocardiographic data of the ratio of peak early 
diastolic transmitral flow (TMF) velocity (E) to peak early 
diastolic mitral annular velocity (e′) at baseline and at 
both 12 and 24 months (Fig. 1).
Echocardiographic examination
Echocardiography was performed in a standard man-
ner using commercially available ultrasound diagnostic 
machines with various hemodynamic parameters being 
measured at each institution. The recordings and meas-
urements were performed in accordance with the guide-
lines issued by the American Society of Echocardiograph 
[19]. TMF velocity was recorded from the apical long-
axis or four-chamber view. The ratio of the peak early 
diastolic (E) and the peak atrial systolic (A) TMF veloci-
ties was calculated. The deceleration time  (DT) of early 
TMF velocity was also measured. The mitral annular 
motion velocity pattern was recorded from the apical 
four-chamber view with the sample volume located at the 
lateral or septal side of the mitral annulus using pulsed 
tissue Doppler echocardiography. The mean peak early 
diastolic mitral annular velocity (e′) in the septal and 
lateral side was measured, and the ratio of E to e′ (E/e′) 
then calculated as a marker of LV filling pressure. In 
addition to these diastolic parameters, routine echocar-
diographic parameters were also measured and included 
Fig. 1 Study participant flow diagram. E/e′: ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e′)
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LV end-diastolic dimensions (LVDd) and LV end-systolic 
dimensions (LVDs) measured from M-mode or 2-dimen-
sional echocardiogram of the LV. Fractional shortening 
was calculated as (LVDs—LVds)/LVDdx100. The LV ejec-
tion fraction (LVEF) was measured and calculated from 
the apical two- and four-chamber view using a modified 
Simpson’s method. LV mass was calculated as reported 
previously [20]. Relative wall thickness was calculated 
as two times posterior wall thickness divided by LVDd 
[21]. All Doppler recordings were performed during an 
end-expiratory breath hold. The mean values of three 
consecutive cardiac cycles were used in the analysis. 
Measurement and interpretation of the echocardiogra-
phy was performed locally at each institution. The read-
ers were blinded to the patients’ assignment to treatment.
Laboratory examination
Blood samples were collected at baseline and after 12 
and 24  months. The parameters analyzed are listed in 
Table 1. The serum levels of N-terminal pro-brain natriu-
retic peptide (NT-proBNP) and high-sensitive CRP were 
measured in a centralized laboratory (SRL Co. Tokyo, 
Japan) using an electrochemiluminescence immunoassay 
(ECLIA) and nephelometry, respectively.
Statistical analysis
Data were expressed as mean ±  standard deviation for 
normally distributed variables, median and interquar-
tile range for variables with a skewed distribution, and 
frequencies (%) for categorical variables. All reported 
probability values were two-sided with a p value  <0.05 
considered statistically significant. The percentage 
changes in the variables during the study period were 
calculated as (values obtained at 12 or 24  months after 
treatment randomization—the baseline value)/base-
line value. The differences between the two groups were 
assessed, where appropriate, by either the Student’s t test, 
Mann–Whitney test, or Fisher’s exact test. Variables with 
a skewed distribution were analyzed in the analysis of 
covariance after logarithmic conversion. We performed 
baseline-adjusted and multivariable regression analysis to 
confirm differences between the two groups. All the anal-
yses were conducted using the JMP software program, 
version 12.1.0 (SAS Institute Inc., Cary, NC, USA).
Results
Clinical characteristics
Table 1 shows a comparison of the clinical characteris-
tics at baseline and at 24 months and baseline-adjusted 
changes after 24  months of glycemic control between 
the two patient groups. There was no difference in body 
mass index and blood pressure between the groups 
throughout the study, while heart rate was increased 
in the sitagliptin group at 24  months. Although more 
than 70% of the subjects had hypertension, blood pres-
sure was well controlled in both groups. Other param-
eters, such as lipid and renal profiles, were similar in 
the two groups throughout the study. The incidence of 
a previous history of CV diseases, including heart fail-
ure was not different in the two groups. Although the 
use of background medications for hypertension, dys-
lipidemia, or diabetes at baseline was also comparable 
in the groups, the incidence of some types of antidia-
betic agent increased during the treatment period. This 
was especially apparent in the conventional group, pos-
sibly due to many patients achieving the glycemic con-
trol goal (HbA1c  <6.2%) set in the PROLOGUE study 
protocol.
Glycemic control and neurohumoral effects
The levels of fasting plasma glucose, HbA1c, and 1, 5 AG 
were similar at baseline in the two groups and there were 
no significant changes in these parameters during the 
24  months of treatment between the groups (Table  1). 
These results indicate similar degrees of improved gly-
cemic control had been achieved. The serum levels of 
NT-proBNP and high-sensitive CRP were also similar at 
baseline and after 24 months of treatment.
Echocardiographic parameters
A comparison of echocardiographic parameters at 
baseline and after 24  months of treatment and base-
line-adjusted changes after 24  months of treatment in 
both groups is shown in Table  2. Although baseline 
E/e′ was significantly higher in the sitagliptin group 
than in the conventional group, the baseline-adjusted 
change in E/e′ during 24  months of treatment was sig-
nificantly lower in the sitagliptin group than in the 
conventional group (Fig.  2a). Analysis of covariance 
showed this difference remained significant (sitagliptin 
group, −30.9  ±  9.8%/24  months; conventional group, 
−11.0 ± 9.0%/24 months; p = 0.001, Table 3), even after 
adjustment for various confounding factors, such as age, 
sex, baseline systolic blood pressure, baseline HbA1c, 
history of CV diseases, history of heart failure, baseline 
medications for diabetes, baseline E/A, baseline LVEF, 
and baseline LV mass index. Other parameters relevant 
to diastolic function such as e′, E/A, and DT were simi-
lar in the two groups during the 24 months of treatment 
(Table  2; Fig.  2b). There were also no significant differ-
ences in parameters of cardiac structure and systolic 
function at baseline and 24 months, or baseline-adjusted 
changes after 24  months of treatment between the two 
groups (Table 2; Fig. 2c, d).
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































: Convenonal group (n=55)






0M 12M 24M 0M 12M 24M
0M 12M 24M 0M 12M 24M
Least square mean ± standard error
a b
dc
Fig. 2 Percentage changes in E/e′, e′, LVEF, and LVMI at 12 and 24 months in the two treatment groups. Each graph shows sex-, age- and baseline-
adjusted least square means (±standard error) at 12 and 24 months. The %change values were calculated as (24 or 12 month data-baseline)/base-
line. E/e′ at 24 months shows significant difference between the two groups. E peak early diastolic transmitral flow velocity, e′ peak early diastolic 
mitral annular velocity, LVEF left ventricular ejection fraction, LVMI left ventricular mass index. *p = 0.002 vs. sitagliptin group
Table 3 Factors associated with change in E/e′ from baseline to 24 months
Model 1 means ANCOVA adjusted for baseline E/e′. Model 2 were adjusted for Model 1 and sex, age. Model 3 were adjusted for Model 2 and systolic blood pressure, 
HbA1c, cardiovascular disease, chronic heart failure, α-glucosidase inhibitor, bigunaide, glinide, sulfonylurea, thiazolidinedione, LV ejection fraction, LV mass index, 
whose data were obtained at baseline examination
Abbreviations, see Tables 1 and 2
Model 1 Model 2 Model 3
N = 115, R = 0.26 N = 115, R = 0.27 N = 115, R = 0.55
β p value β p value β p value
Sitagliptin −8.910 0.006 −8.887 0.007 −9.959 0.001
E/e′ −0.094 0.889 −0.159 0.820 −0.240 0.716
Male gender 0.674 0.845 0.149 0.966
Age 0.330 0.392 −0.005 0.990
Systolic blood pressure −0.293 0.095
HbA1c 6.614 0.272
Cardiovascular disease −5.631 0.142
Chronic heart failure 10.819 0.070





LV ejection fraction 0.178 0.602
LV mass index 0.348 <0.001
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Discussion
The present study was a subgroup analysis of the PRO-
LOGUE trial that focused on the effect of sitagliptin on 
echocardiographic parameters of diastolic function. The 
key finding of the study was that addition of sitagliptin 
to conventional diabetic care significantly attenuated the 
increase in echocardiographic parameters of diastolic 
function (E/e′), relative to conventional treatment alone. 
On the other hand, changes in other parameters such as 
LV size and LVEF did not differ between the two groups. 
We also found no significant differences in the biomark-
ers measured during the study. It is known that metabolic 
disturbances and diabetes are associated closely with 
cardiac diastolic dysfunction such as diabetic cardiomyo-
pathy, and there is also evidence that patients with diabe-
tes and an increased E/e′ have higher mortality [22, 23]. 
Given these results, it appears that sitagliptin treatment 
may have a protective effect on cardiac diastolic function, 
leading to improved prognosis independent of glycemic 
control and blood pressure.
Recently we demonstrated a possible effect of sitaglip-
tin on carotid atherosclerosis [18], endothelial function 
[24], and arterial stiffness [25] using data of the PRO-
LOGUE study. This series of studies did not show ben-
eficial effects of sitagliptin treatment on these variables, 
relative to conventional glucose-lowering treatment with 
the exception of incretin-related agents, with better gly-
cemic control being observed in the sitagliptin treatment 
group. In contrast, there is another report that additional 
administration of DPP-4 inhibitors, including sitagliptin, 
to conventional antidiabetic regimes significantly attenu-
ated the progression of carotid IMT [26, 27]. Although 
the participants’ backgrounds including age, concomitant 
agents, and severity of diabetes differed between these 
studies [18], these findings suggest that DPP-4 inhibitors 
at least cause no harm to the vasculature and are useful 
for glycemic control in the usual clinical settings. The 
findings are also consistent with the results of a large CV 
outcome trial [13]. This led us to investigate the effect of 
sitagliptin on cardiac function and biomarkers in the cur-
rent sub-group analysis of the PROLOGUE study data.
DPP-4 inhibitors promote glucose-dependent insulin 
secretion and suppress glucagon secretion by inhibiting 
the activity of an enzyme which inactivates endogenous 
incretin like glucagon-like peptide-1 (GLP-1) and gas-
tric inhibitory polypeptide. This leads to improved post-
prandial hyperglycemia similar to that seen with the 
normal physiological response. DPP-4 inhibitors do not 
cause weight gain and a single administration is unlikely 
to induce hypoglycemia. It is therefore relatively easy to 
use DPP-4 inhibitors safely in the elderly and patients 
with renal dysfunction. To date, the three randomized 
clinical trials mentioned above have reported non-infe-
riority, relative to placebo, for CV outcomes in patients 
with T2DM with high cardiovascular risk or established 
CV disease [11–13]. In particular, the rate of hospitaliza-
tion for heart failure was similar between sitagliptin and 
placebo treatments in the TECOS trial [13], despite the 
SAVOR-TIMI 53 trial showing that saxagliptin, another 
DPP-4 inhibitor, significantly increased the hospitali-
zation rate [12]. However, because these trials did not 
fully investigate CV physiological functions and relevant 
biomarkers, it proved difficult to determine how DPP-4 
inhibitors affected cardiac function. Mechanistic studies 
using these surrogate markers are therefore required to 
determine the possible actions of DPP-4 inhibitors on the 
CV system.
Accumulated evidence suggests that patients with 
TD2M often exhibit LV diastolic dysfunction and heart 
failure due to underlying metabolic derangement, such as 
insulin resistance, independent of hypertension and cor-
onary artery disease (CAD) [28–30]. Recent studies have 
also demonstrated that DPP-4 activity correlates with 
cardiac systolic and diastolic dysfunction and remodeling 
via several molecular pathways, such as increased inflam-
mation and altered angiogenesis [31–34]. Experimental 
studies have shown that sitagliptin improved survival 
rate and cardiac function in an ischemia–reperfusion 
mice model [35] and reduced infarction size in a myocar-
dial infarction mice model [36]. Long-term administra-
tion of sitagliptin was also shown to suppress the onset 
of heart failure in a rat model of heart failure [31]. A 
meta-analysis of clinical trials also described the advan-
tages of DPP-4 inhibitors on risk reduction in CV events 
and death compared with other antidiabetic agents [37]. 
Sitagliptin treatment in T2DM patients with CAD also 
improved parameters of diastolic function and cardiac 
dysfunction due to post-ischemic stunning during dob-
utamine stress echocardiography [38]. In contrast, sit-
agliptin treatment did not improve systolic function in 
T2DM patients with ischemic heart failure [39]. Further-
more, Oe et  al. [40] reported that sitagliptin treatment 
in T2DM patients with LV diastolic dysfunction was not 
associated with improvement in the relevant echocardio-
graphic parameters. As a consequence of these different 
findings the therapeutic effect of DPP-4 inhibitors on 
cardiac function remains controversial.
In the present study, adding sitagliptin to usual diabe-
tes treatment significantly attenuated the annual increase 
in E/e′, suggesting a preventive effect on LV compliance 
and diastolic dysfunction. However, sitagliptin treat-
ment did not affect other echocardiographic parameters 
of systolic function and cardiac structures or other clini-
cal variables, such as NT-proBNP, blood pressure, and 
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glycemic control. Comparison with a previous study in 
which sitagliptin did not improve diastolic dysfunction 
[40] showed the following differences: (1) all partici-
pants in the previous study were diagnosed with diastolic 
dysfunction at baseline; (2) the treatment period was 
6  months vs. 24  months in the PROLOGUE study; (3) 
the comparator was voglibose vs. any antidiabetic agents 
except for incretin-related in the PROLOGUE study. 
While these differences may have affected the results of 
the studies, the precise mechanisms by which sitaglip-
tin suppressed the increase in diastolic parameter values 
were not confirmed in our study. As reported previ-
ously [40], the increased incidence of concomitant use of 
thiazolidinediones in the conventional group may have 
enhanced the acceleration of E/e′ values. Nogueira et al. 
also reported that beneficial effects in LV diastolic func-
tion were observed in T2DM patients on insulin treated 
with sitagliptin, while the effects were not as apparent in 
T2DM patients treated with insulin only [41]. That study 
also reported a possible association between the sitaglip-
tin-mediated improvement in diastolic dysfunction and 
increase in plasma GLP-1 levels. However, we did not 
measure this incretin in the current study. It is thought 
that GLP-1 has a wide spectrum of CV protective effects 
[42]. In fact, treatment with a GLP-1 agonist, one of the 
incretin-related agents, was shown to improve diastolic 
function beyond and independent of glycemic control 
[43]. Because there remains clinical caution regarding 
DPP-4 inhibitor-induced heart failure [44, 45], further 
experimental and clinical research is required to eluci-
date the precise mechanisms by which DPP-4 inhibitors 
affect diastolic function and heart failure in patients with 
T2DM.
Limitations
The present study was a sub-analysis of the PROLOGUE 
study. Because echocardiography was a voluntary meas-
urement in the PROLOGUE study and not performed 
in all participants, the number of patients in this study 
was small and included only Japanese subjects. Whether 
or not echocardiography was performed was left to the 
judgment of each researcher and therefore selection bias 
could not be fully excluded. The sample size may there-
fore be underpowered and accordingly the clinical impli-
cations may be limited. In addition, the PROLOGUE 
study recruited patients with and without history of heart 
failure at baseline, with patients with a NYHA functional 
classification of III and IV being excluded. Because most 
patients had no history of heart failure evident at base-
line, we did not determine whether there were differences 
in the effects of sitagliptin on diastolic function between 
patients with or without heart failure. Further studies on 
a larger number of subjects are needed to assess whether 
longer-term DPP-4 inhibitor treatment is safe and has 
beneficial effect on cardiac function in T2DM patients 
with or without overt heart failure.
Conclusions
Our present sub-group analysis from the PROLOGUE 
study demonstrated that adding sitagliptin to conven-
tional antidiabetic regimens for 24  months in patients 
with T2DM attenuated the annual exacerbation in the 
echocardiographic parameter of diastolic dysfunction, 
E/e′, independent of other clinical variables such as blood 
pressure and glycemic control. These results suggest that 
sitagliptin is potentially a beneficial agent for diastolic 
function in patients with T2DM.
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